EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of Intranasal Esketamine in Treatment‐Resistant Depression: A Six‐Month Real‐World Follow‐Up Study of Depressive Symptoms, Hopelessness, and Suicide Risk

Maurizio Pompili iD, Maria Anna Trocchia, Ludovica Longhini, Eva Dispenza, Cristina Di Legge, Salvatore Sarubbi, Denise Erbuto, Isabella Berardelli

Human Psychopharmacology: Clinical and Experimental · 2025

DOI: 10.1002/hup.70008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Psychopharmacology: Clinical and Experimental, 2025. Verfasst von Maurizio Pompili und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Centre, Sant'Andrea Hospital, Sapienza University of Rome, Rome, It…. Hauptthemen laut MEDLINE: Ketamine, Depressive Disorder, Treatment-Resistant, Suicidal Ideation, Antidepressive Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Treatment‐resistant depression is one of the most significant clinical challenges in psychiatric practice. The primary aim of the present study was to assess the efficacy and tolerability of intranasal esketamine on depressive symptoms in a real‐world outpatient setting. A secondary objective was to explore the potential benefits of intranasal esketamine on hopelessness and suicide risk (suicidal ideation and suicide attempts).

Methods

Twenty‐one patients diagnosed with treatment‐resistant depression were treated with intranasal esketamine. Depressive symptoms (MADRS and BDI), suicide risk (C‐SSRS), and hopelessness (BHS) were assessed. We conducted a mixed model for repeated measures analysis to evaluate changes from baseline (T0), 3‐month follow‐up (T1), and 6‐month follow‐up (T2).

Results

Results indicated that depressive symptoms decreased over time. Specifically, both clinician and self‐report measures show lower levels of depressive symptoms at 3‐month and 6‐month follow‐up. We also found a significant decrease in the presence of suicidal ideation between T0 and T2. Finally, patients also reported a reduction in hopelessness levels over time.

Conclusions

Our findings indicate an overall response regarding depressive symptoms, hopelessness, and suicidal ideation after esketamine in treatment‐resistant depression at 3‐month and 6‐month follow‐up assessments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetamineDepressive Disorder, Treatment-ResistantSuicidal IdeationAntidepressive AgentsHopeHumansMaleFemaleFollow-Up StudiesAdultAdministration, IntranasalMiddle AgedTreatment OutcomeSuicide, Attempted

Stichwörter der Autor:innen

esketaminesuicide preventionsuicide risktreatment‐resistant depression

Substanzen

KetamineEsketamineAntidepressive Agents

Autor:innen und Institutionen

  • Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Centre, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
  • Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
  • Psychiatry Residency Training Program, Faculty of Medicine and Psychology, Sapienza University of Rome, Psychiatry Unit, Sant'Andrea Hospital, Rome, Italy.

ORCID-Profile: Maurizio Pompili

Zitieren

APA

Pompili, M., Trocchia, M. A., Longhini, L., Dispenza, E., Di Legge, C., Sarubbi, S., Erbuto, D., & Berardelli, I. (2025). Efficacy of Intranasal Esketamine in Treatment‐Resistant Depression: A Six‐Month Real‐World Follow‐Up Study of Depressive Symptoms, Hopelessness, and Suicide Risk. Human Psychopharmacology: Clinical and Experimental. https://doi.org/10.1002/hup.70008

Vancouver

Pompili M, Trocchia MA, Longhini L, Dispenza E, Di Legge C, Sarubbi S, et al. Efficacy of Intranasal Esketamine in Treatment‐Resistant Depression: A Six‐Month Real‐World Follow‐Up Study of Depressive Symptoms, Hopelessness, and Suicide Risk. Human Psychopharmacology: Clinical and Experimental. 2025. doi:10.1002/hup.70008

BibTeX
@article{Pompili2025,
  author = {Pompili, Maurizio and Trocchia, Maria Anna and Longhini, Ludovica and Dispenza, Eva and Di Legge, Cristina and Sarubbi, Salvatore and Erbuto, Denise and Berardelli, Isabella},
  title = {Efficacy of Intranasal Esketamine in Treatment‐Resistant Depression: A Six‐Month Real‐World Follow‐Up Study of Depressive Symptoms, Hopelessness, and Suicide Risk},
  journal = {Human Psychopharmacology: Clinical and Experimental},
  year = {2025},
  doi = {10.1002/hup.70008}
}
Kostenlos starten →